ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The advent of tyrosine kinase inhibitors (TKIs) that target BCR-ABL1 has dramatically changed the Philadelphia chromosome-positive (Ph+) CML therapeutic landscape (4).